

CLAIMS

1. A method of treating migraines, comprising:
 - a) providing i) a patient having one or more symptoms of a migraine and ii) a formulation comprising dihydroergotamine;
 - 5 b) administering said formulation to said patient sublingually under conditions such that said one or more symptoms of said migraine are reduced.
2. The method of Claim 1, wherein said dihydroergotamine is a pharmaceutically accepted salt.
3. The method of Claim 1, wherein said dihydroergotamine is a pharmaceutically accepted base.
4. The method of Claim 1, wherein said sublingual administration is via a liquid.
5. The method of Claim 4, wherein said liquid is administered by a spray.
6. The method of Claim 4, wherein said liquid is administered by drop.
7. The method of Claim 1, wherein said sublingual administration is via a paste or gel.
8. The method of Claim 1, wherein said sublingual administration is via a tablet or compressed powder.
9. The method of Claim 1, wherein said method additionally comprises the co-administration of at least one other pharmaceutically accepted compound.
10. The method of Claim 9, wherein said pharmaceutically accepted compound is a non-vasodilating treatment for migraine.
11. The method of Claim 1, wherein said therapeutic formulation of DHE additionally comprises at least one pain reliever.
12. The method of Claim 1, wherein said therapeutic formulation of DHE additionally comprises at least one antiemetic.
13. The method of Claim 1, wherein said sublingual administration is via a fast dissolve formulation.
14. The method of Claim 1, wherein said formulation additionally comprises at least one effervescent agent.
15. The method of Claim 1, wherein said formulation additionally comprises at

least one pH adjusting agent.

16. The method of Claim 1 wherein, said formulation additionally comprises at least one bio/mucoadhesion agent.
17. The method of Claim 16 wherein, said formulation additionally comprises at least one disintegrant.

5